Navigation Links
Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
Date:9/4/2007

Sources Cite China as Having the Highest Mortality Rate of Asthma in the

World, and Decision Resources Finds Low Diagnosis Rates and Low

Drug-Treatment Rates as a Possible Rationale

WALTHAM, Mass., Sept. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the asthma drug market in China will experience dramatic growth, due to an expanding prevalent population. According to the new Emerging Markets report entitled Asthma in China, the diagnosed asthma population will increase 57 percent in the next five years. An expanding population will be the key driver of this dramatic growth, but increases in the uptake of more expensive drugs, such as the combination product Seretide from GlaxoSmithKline, advocacy and promotion by the Chinese Asthma Alliance (a coordinated effort that promotes asthma prevention and treatment, improved physician education, and initiation of asthma studies), and an expanding middle class will affect the expanding drug market as well.

The report also finds that currently, there are significant barriers to diagnosis, such as the lack of disease awareness, difficulty establishing a differential diagnosis from other respiratory diseases, prohibitive cost of medical attention, lack of diagnostic technology, difficulty discerning variable symptoms (especially in a wheezing child), and the social stigma of asthma (individuals are embarrassed by not being able to breathe and therefore do not seek treatment for their symptoms). Chinese physicians also struggle with low compliance rates among their patients, further constraining optimal drug sales.

"Although the current asthma diagnosis and drug-treatment rates in China are low, the China Asthma Alliance is making strides in implementing new practices to better identify and treat patients," said Vickie Lai, analyst at Decision Resources. "This change presents an opportunity for multinational corporations (MNCs) to reach a larger potential patient population."

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess their commercial opportunity for Western brands

in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou

-- and in the high-growth second-tier markets of Tianjin, Wuhan,

Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese 5-year market forecast at the

drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc., ( http://www.DecisionResources.com ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Obesity And Expanding Waistlines the next Epidemic in USA
2. Art of Living concept expanding around the globe
3. Expanding Price Control Detrimental for Pharma Companies: CII
4. Expanding waistlines: Only a tip of the iceberg?
5. AIDS More Prevalent Among Teenage Girls In The US
6. Fatigue, Prevalent Among Patients Treated For Breast Cancer
7. New PPUD Syndrome Prevalent Among Indian Doctors In Britain
8. Intermittent Explosive Disorder is More Prevalent Now Than Before
9. Aids Seems More Prevalent Among Goan’s – Governor Visiond
10. Prevalent Prescription Drugs Abuse in the US
11. Researchers Warn That Whooping Cough Is Still Very Prevalent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first ... the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions ... activity levels decline over time. The study, presented today at the American ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... ... 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the 2017 ... , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
Breaking Medicine Technology: